BPC-157 15 mg
Also known as · Body Protection Compound 157 · Pentadecapeptide BPC 157
15-residue synthetic pentadecapeptide. Most extensively studied in rodent tendon, ligament, skin, and gastric-mucosal models.
Chemistry quick-facts
- CAS
- 137525-51-0
- Formula
- C62H98N16O22
- MW
- 1419.55 Da
- Length
- 15 aa
- Status
- Preclinical only. No completed human clinical trials. The published evidence base is extensive rodent-model work, primarily from the Sikirić group in Zagreb.
- Purity (HPLC)
- ≥ 99.4%
Mechanism of action
Proposed: modulation of nitric-oxide synthesis, VEGFR-2 signalling, FAK–paxillin cytoskeletal pathways. Specific molecular target not conclusively identified.
Research context
BPC-157 (Body Protection Compound 157) is a 15-residue synthetic peptide, first described in the 1990s as a fragment of a larger gastric-juice protein. Reported as stable in human gastric juice over extended periods.
The preclinical literature — mostly from the Sikirić group at the University of Zagreb — covers tendon, ligament, gut-mucosal, and vascular indications. Human clinical trials are absent.
Published studies
A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.
- Sikirić P, et al. (2013). Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design.
- Chang CH, et al. (2011). BPC 157 on tendon healing. Journal of Applied Physiology.
- Seiwerth S, et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology.
Reconstitution
- Solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- · Inject diluent slowly down the side of the vial onto the cake.
- · Swirl gently — do not shake.
- · Solution should be clear and colourless. Discard if not.
Storage
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life — sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
FAQ
Why no human clinical data?+
No Phase 2/3 human trials have been completed. The evidence base is predominantly rodent models. Omega Grade describes it honestly — extensive preclinical literature, minimal clinical data.
This page summarises the research literature on BPC-157 15 mg for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.
- ResearchBPC-157 + TB-500 10/10 mg kit
The most-requested regenerative-peptide kit in the catalogue. BPC-157 and thymosin β-4 combined in a single lyophilised vial — commonly paired in prec
- ResearchTB-500 10 mg
Synthetic full-length 43-residue thymosin β-4. The most abundant intracellular actin-sequestering peptide in mammalian tissues.
- ResearchBPC-157 oral (60 × 500 mcg tablets)
Oral tablet presentation of BPC-157. The Sikirić literature notes stability of BPC-157 in gastric juice; this format enables oral-route research proto
- ComparisonBPC-157 vs TB-500 — research differences and combined-use literature
BPC-157 and TB-500 (thymosin beta-4 fragment) are the two most-studied research peptides in tissue-repair literature. Their mechanisms differ — what the research shows, and why they're often paired in protocol papers.
- Biomarkerhs-CRP 2.5 mg/L
High-sensitivity C-reactive protein at 2.5 mg/L sits in the 'intermediate cardiovascular risk' category most cardiology research uses. What it measures, what drives it, and how to interpret your number.
- ComparisonBPC-157 acetate vs arginate — salt forms compared
BPC-157 is sold as either the acetate or arginate salt. The arginate form has improved stability across pH variations; acetate is the historical default.